Article

Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology

Author(s):

Julianne Mobilian
Conferences|ASCRS

ICYMI: Here's what's in the 2019 pipeline

Rajesh Rajpal, MD, Chief Medical Officer of Avedro, Inc., provides a company update on Epi-on crosslinking (CXL) and PiXL technology during the 2019 ASCRS conference in San Diego.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Related Content
Study shows ceftriaxone found effective in treating congenital syphilis
June 11th 2025

Study shows ceftriaxone found effective in treating congenital syphilis

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

GenEditBio doses first patient in investigator-initiated trial of GEB-101 for TGFBI corneal dystrophy
June 9th 2025

GenEditBio doses first patient in investigator-initiated trial of GEB-101 for TGFBI corneal dystrophy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Ophthalmologists present data on perfluorohexyloctane eye drops
June 6th 2025

Ophthalmologists present data on perfluorohexyloctane eye drops

(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
June 4th 2025

The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

© 2025 MJH Life Sciences

All rights reserved.